Business Wire

Adoption of New Therapy for Autoimmune Diseases to Benefit Millions of Patients in Over 100 Countries

Jaa

Professor Tadamitsu Kishimoto of the Osaka University, winner of the King Faisal International Prize for Medicine 2017, has stated that more than 100 countries, including Saudi Arabia, have adopted an effective biological approach in the treatment of autoimmune diseases, raising hopes for millions of people around the world who suffer from such diseases. The new treatment is significant considering that autoimmune diseases, which result from the failure of immune system cells to differentiate between the body’s tissues and cells, and alien tissues and cells, cause the body to fight against itself.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170708005001/en/

Professor Tadamitsu Kishimoto (Photo: ME NewsWire)

Professor Tadamitsu Kishimoto (Photo: ME NewsWire)

Professor Kishimoto, who was recently awarded the prestigious prize for the discovery of endogenous chemical interleukin-6’s (IL-6) pathway and its role in inflammatory and autoimmune diseases, said this while delivering a lecture organised by the King Faisal International Prize at the College of Medicine at the King Saud University in Riyadh. This lecture reflected the King Faisal International Prize’s efforts to promote the dissemination, transfer and localisation of knowledge by honouring humanitarian achievements and celebrating everything that serves people and improves their wellbeing.

A world-renowned immunologist, Professor Kishimoto has, through his research during the last 30 years, developed an IL-6 receptor-blocking antibody that has been recognized as the first approved treatment for diseases such progressive sclerosis and rheumatoid arthritis.

“The discovery of IL-6 receptor-blocking antibody has led to a major breakthrough in the treatment of autoimmune diseases. It has been approved for treatment in over 100 countries, including Saudi Arabia, Japan, the EU, and the US. Today almost one million people suffering from such diseases are being successfully treated with this antibody,” stated Kishimoto.

Besides being an immune protein, IL-6 is responsible for fever in autoimmune, infectious or non-infectious diseases, and is produced in the body wherever there is inflammation. IL-6 is implicated in a wide variety of inflammation-associated diseases, including diabetes mellitus and systemic juvenile rheumatoid arthritis.

The discovery of the antibody has not only led to the treatment of inflammatory diseases but has also paved the way for the training of several immunologists in all parts of the world, added Professor Kishimoto.

The King Faisal International Prize in Medicine has earlier been awarded to two researchers from Japan. Tetsuro Fujiwara was the first recipient when he shared the award with Bengt A. Robertson of Sweden in 1996 for research on the management of Neonatal Respiratory Distress Syndrome. Shinya Yamanaka was the second winner, sharing the prize in 2011 with James Alexander Thomson of USA. Yamanaka later won the Nobel Prize in 2012.

To know more about King Faisal International Prize, visit our website:

www.kfip.org

*Source: ME NewsWire

Contact information

for King Faisal Foundation
Hussain Abu Hajer, +966568685008
Hussain@hadathgroup.com
or
Rima Abuobaid
UAE Mob: +971509155921
KSA Mob: +966556890730
rima@hadathgroup.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis22.2.2018 00:01Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 21:00Tiedote

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized

Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 19:30Tiedote

Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin

Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 19:30Tiedote

Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi

H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group21.2.2018 17:02Tiedote

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Puerto de Indias Group (“Puerto de Indias” or the “Company”), with the goal of accelerating the Company’s growth initiatives and supporting its expansion into international markets. Headquartered in Seville, Spain, Puerto de Indias was founded by Jose Antonio and Francisco Rodriguez Fernandez, and has become in a short period of time the leading player in the Rosé Gin market in Spain. Puerto de Indias has in place an ambitious international expansion plan targeting the development of a commercial network in Europe, the U.S., and Latin America, as well as strategic alliances with strong international distributors. Leopoldo Reaño, Principal at H.I.G. Europe, commented on the transaction: “We are thrilled to have the opportunity to support the management team led by Jose Antonio an

Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 16:02Tiedote

Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme